GLP – 3 (R)

Product Overview:

Product Name: GLP – 3 (R)
Quantity: 10mg
Molecular Formula: C222H340N60O68
Molecular Weight: ~5100 Da
Research Use Only. Not for Human Consumption.

Research Applications:

1. Triple Receptor Agonism and Metabolic Pathways

GLP – 3 (R) is a novel investigational peptide designed to activate three key metabolic receptors: glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This multi-receptor profile has made it an important compound in the study of endocrine cross-talk and metabolic regulation [1].

Its structure is engineered to balance agonism across these receptors, enabling researchers to study synergistic effects on insulin secretion, appetite regulation, and lipid oxidation in animal and in vitro models.

2. Energy Expenditure and Adipose Tissue Research

In preclinical studies, GLP – 3 (R) has been observed to increase energy expenditure and reduce adiposity in rodent and primate models. The glucagon receptor agonism is associated with elevated thermogenesis and lipid metabolism, while GIP and GLP-1 receptor signaling help modulate insulin response and satiety [2].

This peptide is frequently utilized in research on brown adipose tissue activation, mitochondrial efficiency, and lipid mobilization, particularly under conditions of diet-induced obesity or metabolic stress.

3. Glucose Homeostasis and Insulin Sensitivity Models

GLP – 3 (R)’s GLP-1 and GIP receptor activity makes it useful in exploring glucose homeostasis. GLP-1R agonism enhances glucose-stimulated insulin secretion, delays gastric emptying, and suppresses glucagon, while GIPR agonism can enhance β-cell function. This triple-agonist profile provides a powerful tool for dissecting mechanisms of glucose utilization and insulin sensitivity in preclinical diabetes research [3].

It is of special interest in dual- or triple-pathway modulation models used to study incretin biology and glucose-insulin dynamics in vivo.

4. Hormonal Feedback and Appetite Regulation

Studies in rodent models have shown that GLP – 3 (R) significantly reduces food intake via central and peripheral mechanisms. Its interaction with the hypothalamic melanocortin pathway and gut-derived satiety hormones positions it as a candidate for studying complex neuroendocrine signaling in appetite regulation [4].

Researchers often investigate how GLP-1 and GIP signaling intersect in the brainstem and hypothalamus to influence feeding behavior, making GLP – 3 (R) a compound of high interest in obesity and metabolic signaling research.

Referenced Citations:

1. Coskun T, et al. “A triple hormone receptor agonist for obesity treatment.” PubMed
   Source: Cell – Characterization of GLP – 3 (R)’s activity at GLP-1R, GIPR, and GCGR.
2. Day JW, et al. “Multi-agonist peptides for metabolic disease.” PubMed
   Source: Nature Reviews Drug Discovery – Mechanistic insight into glucagon-based multi-agonists.
3. Finan B, et al. “Unimolecular peptides for metabolic disease models.” PubMed
   Source: Science Translational Medicine – Preclinical efficacy of triple agonist compounds.
4. Tschöp MH, et al. “Neuroendocrine mechanisms of GLP-1 and GIP co-agonists.” PubMed
   Source: Nature Metabolism – Appetite signaling through incretin pathways.